# A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer

> **NCT01636284** · PHASE2 · COMPLETED · sponsor: **Jennerex Biotherapeutics** · enrollment: 16 (actual)

## Conditions studied

- Hepatocellular Carinoma

## Interventions

- **BIOLOGICAL:** JX-594 recombinant vaccina GM-CSF

## Key facts

- **NCT ID:** NCT01636284
- **Lead sponsor:** Jennerex Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2021-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01636284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01636284, "A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01636284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*